Tunlametinib pill vs chemo for advanced NRAS melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage 3 (cannot be removed) or stage 4 (spread) melanoma with an NRAS gene change.
- You have tried immunotherapy (like checkpoint inhibitors) and it stopped working or you couldn't tolerate it.
- You have at least one tumor that can be measured on a scan.
- You are generally healthy enough for daily activities (ECOG score 0 or 1).
- You have not had major surgery in the last 4 weeks, and your heart and lab tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.